middle.news
AdAlta’s EW-001 CAR-T Therapy Marks Two-Year Cancer-Free Survival in Mesothelioma Patient
8:26am on Wednesday 5th of August, 2026 AEST
•
Biotechnology
Read Story
AdAlta’s EW-001 CAR-T Therapy Marks Two-Year Cancer-Free Survival in Mesothelioma Patient
8:26am on Wednesday 5th of August, 2026 AEST
Key Points
First complete responder survives two years cancer-free
Second complete responder reaches one-year survival
14% overall complete response rate in 14 patients
Manufacturing transfer to Australia underway
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
AdAlta (ASX:1AD)
OPEN ARTICLE